North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:North China Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014101
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Group Corp (NCPC) is a healthcare products provider that manufactures and distributes antibiotic bulks and formulations, vitamins and nutrition products. The company’s products comprise antibiotics, penicillin, amoxicillin, streptomycin sulfate, cefradine, 7-ADCA, vitamin C and vitamin B12. It offers its products in dosage forms of capsules, granules, injections, freeze-dried powder for injection, immunologic and biologic agent, nutrition supplement, tablets, veterinary and biocides products, powder for injection, antineoplastic agents, oral suspension and other formulations. The company markets its products across China. NCPC is headquartered in Shijiazhuang, China.

North China Pharmaceutical Group Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 11
Debt Offering 12
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 12
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 13
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 14
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 16
Acquisition 17
NCPC To Sell North China Pharma Huasheng For US$12 Million 17
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 18
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 19
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 20
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 21
North China Pharmaceutical Group Corp – Key Competitors 22
North China Pharmaceutical Group Corp – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 12
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 13
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 14
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 16
NCPC To Sell North China Pharma Huasheng For US$12 Million 17
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 18
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 19
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 20
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 21
North China Pharmaceutical Group Corp, Key Competitors 22
North China Pharmaceutical Group Corp, Other Locations 23
North China Pharmaceutical Group Corp, Subsidiaries 23

★海外企業調査レポート[North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • United Therapeutics Corp (UTHR):医療機器:M&Aディール及び事業提携情報
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …
  • MPC Munchmeyer Petersen Capital AG (MPCK):企業の財務・戦略的SWOT分析
    Summary MPC Munchmeyer Petersen Capital AG (MPC), a subsidiary of MPC Munchmeyer Petersen & Co GmbH, is an asset and investment management firm. The firm business segments include infrastructure, real estate and shipping. Its real estate business concentrates on micro living or student housing. Its …
  • Newfield Exploration Company:戦略・SWOT・企業財務分析
    Newfield Exploration Company - Strategy, SWOT and Corporate Finance Report Summary Newfield Exploration Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Deluxe Corporation:企業の戦略・SWOT・財務情報
    Deluxe Corporation - Strategy, SWOT and Corporate Finance Report Summary Deluxe Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hibbett Sports Inc:企業の戦略・SWOT・財務分析
    Hibbett Sports Inc - Strategy, SWOT and Corporate Finance Report Summary Hibbett Sports Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Medicines for Malaria Venture:企業のM&A・事業提携・投資動向
    Medicines for Malaria Venture - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medicines for Malaria Venture Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Otto Bock HealthCare GmbH:企業の戦略的SWOT分析
    Otto Bock HealthCare GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Citius Pharmaceuticals Inc (CTXR):企業の財務・戦略的SWOT分析
    Summary Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Min …
  • Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cantex Pharmaceuticals Inc (Cantex Pharmaceuticals), formerly ParinGenix Inc is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combi …
  • Avadel Pharmaceuticals Plc (AVDL)-製薬・医療分野:企業M&A・提携分析
    Summary Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, CNS (narcolepsy), pain, respiratory diseases and diabetes. The company’s product portfolio includes Bloxiverz, Karbinal ER, …
  • Guided Therapeutics Inc (GTHP):医療機器:M&Aディール及び事業提携情報
    Summary Guided Therapeutics Inc (GTI), formerly SpectRx Inc is a biotechnology company that offers platform technology for the early detection of disease that leads to cancer. The company provides products for the non-invasive cervical cancer detection markets. Its products include luviva, a non-inv …
  • Bionomics Ltd (BNO):企業の財務・戦略的SWOT分析
    Summary Bionomics Ltd (Bionomics) is a biopharmaceutical company that discovers and develops treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer's disease. The company provides pipeline products such as BNC210, BNC 105, BNC101 and BNC375, among other …
  • Canadian Solar Inc (CSIQ):企業の財務・戦略的SWOT分析
    Canadian Solar Inc (CSIQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Archroma Management GmbH:企業の戦略的SWOT分析
    Archroma Management GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Alesi Surgical Ltd-医療機器分野:企業M&A・提携分析
    Summary Alesi Surgical Ltd (Alesi Surgical), formerly Asalus Medical Instruments Ltd is a medical device company that develops devices for minimal access surgery. The company offers surgical smoke control system. Its product is used to clear surgical smoke from the visual field and to prevent its re …
  • LM Wind Power Holding AS-エネルギー分野:企業M&A・提携分析
    Summary LM Wind Power Holding AS (LM Wind Power), a subsidiary of General Electric Co, is a component supplier to the wind industry. The company designs and manufactures blades on modular technology featuring modular aerodynamics, modular structure and modular manufacturing tooling. Its blades have …
  • Imperial d.d.:企業の戦略・SWOT・財務分析
    Imperial d.d. - Strategy, SWOT and Corporate Finance Report Summary Imperial d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • HC2 Holdings, Inc.:企業のM&A・事業提携・投資動向
    HC2 Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HC2 Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Antofagasta Plc:企業の戦略・SWOT・財務情報
    Antofagasta Plc - Strategy, SWOT and Corporate Finance Report Summary Antofagasta Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • DaVita Inc.:企業のM&A・事業提携・投資動向
    DaVita Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DaVita Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆